548 related articles for article (PubMed ID: 21642861)
1. Histone deacetylase inhibitors sensitize human non-small cell lung cancer cells to ionizing radiation through acetyl p53-mediated c-myc down-regulation.
Seo SK; Jin HO; Woo SH; Kim YS; An S; Lee JH; Hong SI; Lee KH; Choe TB; Park IC
J Thorac Oncol; 2011 Aug; 6(8):1313-9. PubMed ID: 21642861
[TBL] [Abstract][Full Text] [Related]
2. Sensitization to gamma-irradiation-induced cell cycle arrest and apoptosis by the histone deacetylase inhibitor trichostatin A in non-small cell lung cancer (NSCLC) cells.
Zhang F; Zhang T; Teng ZH; Zhang R; Wang JB; Mei QB
Cancer Biol Ther; 2009 May; 8(9):823-31. PubMed ID: 19270532
[TBL] [Abstract][Full Text] [Related]
3. Myc down-regulation sensitizes melanoma cells to radiotherapy by inhibiting MLH1 and MSH2 mismatch repair proteins.
Bucci B; D'Agnano I; Amendola D; Citti A; Raza GH; Miceli R; De Paula U; Marchese R; Albini S; Felsani A; Brunetti E; Vecchione A
Clin Cancer Res; 2005 Apr; 11(7):2756-67. PubMed ID: 15814658
[TBL] [Abstract][Full Text] [Related]
4. Induction of PIG3 and NOXA through acetylation of p53 at 320 and 373 lysine residues as a mechanism for apoptotic cell death by histone deacetylase inhibitors.
Terui T; Murakami K; Takimoto R; Takahashi M; Takada K; Murakami T; Minami S; Matsunaga T; Takayama T; Kato J; Niitsu Y
Cancer Res; 2003 Dec; 63(24):8948-54. PubMed ID: 14695212
[TBL] [Abstract][Full Text] [Related]
5. Histone deacetylase inhibitor, Trichostatin A, activates p21WAF1/CIP1 expression through downregulation of c-myc and release of the repression of c-myc from the promoter in human cervical cancer cells.
Li H; Wu X
Biochem Biophys Res Commun; 2004 Nov; 324(2):860-7. PubMed ID: 15474507
[TBL] [Abstract][Full Text] [Related]
6. c-Myc down-regulation is involved in proteasome inhibitor-mediated enhancement of radiotherapeutic efficacy in non-small cell lung cancer.
Jung J; Kim EJ; Chung HK; Park HJ; Jeong SY; Choi EK
Int J Oncol; 2012 Feb; 40(2):385-90. PubMed ID: 21947247
[TBL] [Abstract][Full Text] [Related]
7. Histone deacetylase inhibitor quisinostat activates caspase signaling and upregulates p53 acetylation to inhibit the proliferation of HepG2 cells.
Li F; Wang T; Wang Z; Chen X; Liu R
Mol Med Rep; 2017 Nov; 16(5):6094-6101. PubMed ID: 28849080
[TBL] [Abstract][Full Text] [Related]
8. Effect of rapamycin, an mTOR inhibitor, on radiation sensitivity of lung cancer cells having different p53 gene status.
Nagata Y; Takahashi A; Ohnishi K; Ota I; Ohnishi T; Tojo T; Taniguchi S
Int J Oncol; 2010 Oct; 37(4):1001-10. PubMed ID: 20811722
[TBL] [Abstract][Full Text] [Related]
9. Sodium valproate, a histone deacetylase inhibitor, enhances the efficacy of vinorelbine-cisplatin-based chemoradiation in non-small cell lung cancer cells.
Gavrilov V; Lavrenkov K; Ariad S; Shany S
Anticancer Res; 2014 Nov; 34(11):6565-72. PubMed ID: 25368259
[TBL] [Abstract][Full Text] [Related]
10. Histone deacetylase inhibitors VPA and TSA induce apoptosis and autophagy in pancreatic cancer cells.
Gilardini Montani MS; Granato M; Santoni C; Del Porto P; Merendino N; D'Orazi G; Faggioni A; Cirone M
Cell Oncol (Dordr); 2017 Apr; 40(2):167-180. PubMed ID: 28160167
[TBL] [Abstract][Full Text] [Related]
11. HDAC inhibitors: a new radiosensitizer for non-small-cell lung cancer.
Zhu L; Wu K; Ma S; Zhang S
Tumori; 2015; 101(3):257-62. PubMed ID: 25953446
[TBL] [Abstract][Full Text] [Related]
12. The histone deacetylase inhibitor trichostatin A induces cell cycle arrest and apoptosis in colorectal cancer cells via p53-dependent and -independent pathways.
Meng J; Zhang HH; Zhou CX; Li C; Zhang F; Mei QB
Oncol Rep; 2012 Jul; 28(1):384-8. PubMed ID: 22552631
[TBL] [Abstract][Full Text] [Related]
13. Histone deacetylase inhibitor induces cell apoptosis and cycle arrest in lung cancer cells via mitochondrial injury and p53 up-acetylation.
Bao L; Diao H; Dong N; Su X; Wang B; Mo Q; Yu H; Wang X; Chen C
Cell Biol Toxicol; 2016 Dec; 32(6):469-482. PubMed ID: 27423454
[TBL] [Abstract][Full Text] [Related]
14. Histone deacetylase inhibitors induce cell death and enhance the susceptibility to ionizing radiation, etoposide, and TRAIL in medulloblastoma cells.
Sonnemann J; Kumar KS; Heesch S; Müller C; Hartwig C; Maass M; Bader P; Beck JF
Int J Oncol; 2006 Mar; 28(3):755-66. PubMed ID: 16465382
[TBL] [Abstract][Full Text] [Related]
15. Histone deacetylase inhibitors induce in human hepatoma HepG2 cells acetylation of p53 and histones in correlation with apoptotic effects.
Carlisi D; Vassallo B; Lauricella M; Emanuele S; D'Anneo A; Di Leonardo E; Di Fazio P; Vento R; Tesoriere G
Int J Oncol; 2008 Jan; 32(1):177-84. PubMed ID: 18097557
[TBL] [Abstract][Full Text] [Related]
16. Histone Deacetylase Inhibitors Inhibit the Proliferation of Gallbladder Carcinoma Cells by Suppressing AKT/mTOR Signaling.
Zhang P; Guo Z; Wu Y; Hu R; Du J; He X; Jiao X; Zhu X
PLoS One; 2015; 10(8):e0136193. PubMed ID: 26287365
[TBL] [Abstract][Full Text] [Related]
17. Histone deacetylase inhibitor NVP-LAQ824 sensitizes human nonsmall cell lung cancer to the cytotoxic effects of ionizing radiation.
Cuneo KC; Fu A; Osusky K; Huamani J; Hallahan DE; Geng L
Anticancer Drugs; 2007 Aug; 18(7):793-800. PubMed ID: 17581301
[TBL] [Abstract][Full Text] [Related]
18. Synergistic anticancer effects of cisplatin and histone deacetylase inhibitors (SAHA and TSA) on cholangiocarcinoma cell lines.
Asgar MA; Senawong G; Sripa B; Senawong T
Int J Oncol; 2016 Jan; 48(1):409-20. PubMed ID: 26575528
[TBL] [Abstract][Full Text] [Related]
19. Histone deacetylase inhibitors sensitize glioblastoma cells to TRAIL-induced apoptosis by c-myc-mediated downregulation of cFLIP.
Bangert A; Cristofanon S; Eckhardt I; Abhari BA; Kolodziej S; Häcker S; Vellanki SH; Lausen J; Debatin KM; Fulda S
Oncogene; 2012 Nov; 31(44):4677-88. PubMed ID: 22266862
[TBL] [Abstract][Full Text] [Related]
20. Molecular sequelae of histone deacetylase inhibition in human retinoblastoma cell lines: clinical implications.
Poulaki V; Mitsiades CS; Kotoula V; Negri J; McMullan C; Miller JW; Marks PA; Mitsiades N
Invest Ophthalmol Vis Sci; 2009 Sep; 50(9):4072-9. PubMed ID: 19387079
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
